Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience

J Neurooncol. 2023 Aug;164(1):239-247. doi: 10.1007/s11060-023-04395-3. Epub 2023 Jul 14.


Purpose: Belzutifan is a selective inhibitor of hypoxia-inducible factor 2 alpha (HIF-2a) that has emerged as a targeted therapy option for Von Hippel-Lindau (VHL) syndrome-associated tumors with recent FDA approval. There is limited real-world evidence regarding safety and efficacy in CNS hemangioblastoma. Our objective was to report on our clinical experience with belzutifan in adult patients with VHL-associated CNS hemangioblastoma.

Methods: We retrospectively reviewed our institutional experience of belzutifan in adult patients (> 18 years of age at time of therapy) with VHL and craniospinal CNS hemangioblastomas not amenable to surgical resection. The period for study review was October 2021 to March 2023.

Results: 4 patients (all female) with a median age of 36 years at time of belzutifan initiation were included. Median duration of therapy at last follow-up was 11 months (6-17 months). All patients had radiographic response to therapy after a median of 3 months (2-5 months), with maximal response to therapy after a median of 8 months (3-17 months). Therapy was well tolerated, with the most common adverse effect being anemia. No patients had treatment pauses or dose adjustments due to belzutifan-related toxicity. No patients experienced hypoxia.

Conclusion: We showed that belzutifan is safe and well-tolerated with strong disease response for CNS hemangioblastoma in adults with VHL, supporting continued use of belzutifan in this patient population. Future studies should assess duration of treatment, effects of cessation after long-term use, and markers of therapeutic response.

Keywords: Belzutifan; Craniospinal; Hemangioblastoma; Real world; Toxicity; Von Hippel–Lindau.

MeSH terms

  • Adult
  • Central Nervous System / pathology
  • Central Nervous System Neoplasms* / complications
  • Central Nervous System Neoplasms* / drug therapy
  • Female
  • Hemangioblastoma* / pathology
  • Humans
  • Retrospective Studies
  • Von Hippel-Lindau Tumor Suppressor Protein
  • von Hippel-Lindau Disease* / complications
  • von Hippel-Lindau Disease* / drug therapy
  • von Hippel-Lindau Disease* / pathology


  • belzutifan
  • VHL protein, human
  • Von Hippel-Lindau Tumor Suppressor Protein